ISHL HL Update 2021 | Novel approaches in HL
Paul Jan Bröckelmann
• 11 Mar 2021
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, explores the next steps in the treatment and management of Hodgkin lymphoma, including the development of second-generation anti-PD-1 antibodies, CD30-targeting CAR T-cell therapies, as well as combination strategies investigated in relapsed/refractory HL patients. Dr Bröckelmann also touches on areas of unmet needs in HL, including the treatment of older HL patients, the importance of identifying response biomarkers as well as rational combination strategies. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
